Addyi vs Vyleesi: Which FDA-Approved HSDD Treatment Is Right for You?

What Is HSDD and Why Does the Drug Choice Matter?

Hypoactive sexual desire disorder is the most prevalent female sexual dysfunction, affecting an estimated 8 to 10% of U.S. adult women by DSM-5 criteria [1]. Diagnosis requires persistent, low sexual desire that causes personal distress, the distress criterion is non-negotiable under both the DSM-5 and the International Society for the Study of Women's Sexual Health (ISSWSH) clinical practice guideline [2]. Choosing between Addyi and Vyleesi is not simply a matter of preference; the two drugs target different biological pathways, carry different risk profiles, and fit different lifestyle patterns.

A prescriber who picks Vyleesi for a woman with poorly controlled hypertension, or Addyi for a woman who drinks alcohol socially, may expose her to avoidable harm. Getting the indication right also means ruling out causes of low desire that neither drug addresses: genitourinary syndrome of menopause (GSM), relationship factors, untreated depression, and hormonal deficiencies all require separate management [3].

How Addyi (Flibanserin) Works

Flibanserin acts on the central nervous system rather than on blood flow or genital tissue. It is a postsynaptic serotonin 1A agonist and serotonin 2A antagonist, which collectively shift the neurochemical balance in the medial prefrontal cortex toward dopamine and norepinephrine, neurotransmitters associated with sexual motivation [4]. The drug must be taken every night at bedtime; missing doses or taking it at the wrong time increases both hypotension risk and the likelihood of syncope.

The FDA granted approval in August 2015 after Sprout Pharmaceuticals submitted three Phase 3 trials collectively called BEGONIA, SNOWDROP, and DAISY, which enrolled more than 2,400 premenopausal women [5]. Across those trials, women on flibanserin 100 mg reported a statistically significant increase in satisfying sexual events (SSEs) compared with placebo, though absolute effect sizes were modest. In the SNOWDROP trial (N=949), flibanserin produced a mean increase of 0.5 SSEs per 28 days versus 0.2 for placebo (P<0.001) [5].

Alcohol is an absolute contraindication. The FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for Addyi specifically because co-ingestion with alcohol can cause severe hypotension and syncope [6]. Even moderate drinking within several hours of a dose constitutes a contraindication. Strong CYP3A4 inhibitors, including fluconazole, clarithromycin, and grapefruit juice, raise flibanserin plasma levels substantially and are also contraindicated [6].

Common side effects include dizziness (11%), somnolence (11%), nausea (10%), and fatigue (9%) based on pooled Phase 3 data [5]. Because these effects peak during sleep, bedtime dosing reduces their functional impact for most women.

How Vyleesi (Bremelanotide) Works

Bremelanotide activates melanocortin 3 and 4 receptors in the hypothalamus, a pathway distinct from the serotonergic mechanism of flibanserin [7]. The hypothalamic melanocortin system modulates sexual arousal and motivation independently of estrogen levels, which makes Vyleesi theoretically attractive for women whose low desire is not driven by hormonal deficiency.

The drug is supplied as a single-use autoinjector (1.75 mg/0.3 mL) administered subcutaneously into the abdomen or thigh. Women self-inject 45 minutes before anticipated sexual activity; the effect window runs roughly 16 hours [8]. No more than one dose should be used per 24-hour period, and the labeling advises against more than one dose per month for women with cardiovascular risk factors [8].

FDA approval came in June 2019 based on two identical Phase 3 trials, RECONNECT Study A and Study B (combined N=1,267 premenopausal women with HSDD) [9]. In the pooled RECONNECT analysis, bremelanotide increased the Female Sexual Function Index desire domain score by 0.35 points versus 0.13 for placebo (P<0.001) and reduced distress scores on the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) by 11.1 points versus 8.0 for placebo [9].

Transient blood-pressure elevation is the most clinically significant side effect. Systolic blood pressure rises an average of 2 to 4 mmHg for approximately 12 hours post-injection [8]. Women with pre-existing cardiovascular disease, uncontrolled hypertension, or a history of stroke or serious cardiac events should not use bremelanotide [8]. Nausea occurs in approximately 40% of users and is the leading reason for discontinuation [9]. Hyperpigmentation of the face, breasts, or gums develops in roughly 1% of women with long-term use due to off-target MC1R activation [8].

Direct Comparison: Addyi vs Vyleesi Side by Side

Both drugs are FDA-approved for the same narrow indication: acquired, generalized HSDD in premenopausal women. Neither is approved for postmenopausal women, and neither addresses GSM-related symptoms like vaginal dryness or dyspareunia [2].

Scheduling and lifestyle fit. Addyi demands nightly compliance regardless of whether sex is anticipated. Women who travel, work night shifts, or have irregular sleep schedules often struggle with consistent bedtime dosing. Vyleesi fits an on-demand pattern but requires planning 45 minutes ahead and comfort with self-injection.

Alcohol and drug interactions. Addyi carries a REMS-enforced alcohol contraindication with no exceptions [6]. Vyleesi has no alcohol contraindication but requires caution with naltrexone (which may reduce efficacy) [8].

Cardiovascular considerations. Vyleesi is contraindicated in women with cardiovascular disease. Addyi carries a risk of hypotension and syncope, particularly when combined with alcohol or CYP3A4 inhibitors, but is not categorically contraindicated in women with stable cardiovascular disease who do not drink [6].

Efficacy. Head-to-head trial data do not exist. Cross-trial comparisons are limited by different patient populations and outcome measures, but both drugs produce modest improvements over placebo, roughly 0.5 additional SSEs per month above placebo in flibanserin trials, and roughly 0.35 FSFI desire-domain points above placebo for bremelanotide [5, 9]. Neither drug works for every woman. In the RECONNECT trials, 25% of Vyleesi users discontinued due to nausea [9].

A practical decision framework for prescribers and patients:

1. Women who drink alcohol socially: Vyleesi is the only approved option.
2. Women with uncontrolled hypertension or cardiovascular disease: Addyi is the preferred approved option, provided CYP3A4 interactions are screened.
3. Women who prefer spontaneity or dislike injections: Addyi, with the understanding that nightly dosing is mandatory.
4. Women who want treatment only on specific occasions: Vyleesi, with the understanding that 45-minute lead time and potential nausea require planning.
5. Women who are postmenopausal: neither drug is approved; address GSM and hormonal deficiency first.

Vaginal Estrogen vs Systemic HRT for Sexual Symptoms

Low desire in postmenopausal women often has a different root cause than HSDD in premenopausal women. GSM, characterized by vaginal atrophy, dryness, dyspareunia, and recurrent urinary tract infections, is driven by estrogen deficiency, not by a central neurotransmitter imbalance [10]. Addyi and Vyleesi do not treat GSM.

Systemic HRT (oral estradiol, transdermal patches, gels, or sprays) can relieve GSM symptoms in some women, but the dose of estrogen reaching vaginal tissue may be insufficient for full symptom resolution even when systemic menopausal symptoms like hot flashes improve [10]. The 2023 NAMS Menopause Practice: A Clinician's Guide states: "Systemic estrogen therapy does not always provide adequate relief of genitourinary symptoms, and local vaginal therapy may be added" [11].

Local vaginal estrogen, available as cream (Estrace), tablets (Vagifem/Yuvafem), a ring (Estring), or soft-gel inserts (Imvexxy), delivers estradiol directly to vulvovaginal and urethral tissues with minimal systemic absorption [12]. A 2016 Cochrane review of 30 randomized controlled trials (N=6,932) found that vaginal estrogen preparations significantly improved vaginal dryness, dyspareunia, and vaginal pH compared with placebo, with the different formulations showing broadly similar efficacy [13]. The systemic estradiol exposure from vaginal ring and low-dose tablet formulations remains below the threshold of clinical significance in most women [12].

Women who are already on systemic HRT and still experience GSM symptoms may benefit from adding local vaginal estrogen. The two therapies address different tissue targets and are not redundant.

Prasterone vs Vaginal Estradiol

Prasterone (dehydroepiandrosterone, DHEA), marketed as Intrarosa (10 mg vaginal insert), offers a non-estrogen local option for postmenopausal dyspareunia. After vaginal insertion, DHEA is converted locally into estrogens and androgens within vaginal cells, bypassing systemic circulation [14]. The FDA approved prasterone in November 2016 for dyspareunia due to menopause [15].

In the key Phase 3 trials (ERC-213 and ERC-231, combined N=577), daily prasterone significantly improved the most bothersome symptom (MBS) score compared with placebo (P<0.001), with vaginal cell maturation value and pH improving comparably to vaginal estradiol benchmarks [16]. Serum DHEA, testosterone, and estradiol levels after daily 10 mg vaginal insertion remained within or just above normal postmenopausal ranges, and no endometrial proliferation was detected at 52 weeks [16].

How does prasterone compare to vaginal estradiol in practice?

Both reduce dyspareunia and improve vaginal atrophy markers. The 2020 ISSWSH position statement on vulvovaginal atrophy notes that prasterone and local estrogen have comparable efficacy for dyspareunia based on available trial data, and both are appropriate first-line options [17]. Prasterone may be preferred when:

• A woman or her provider prefers to avoid estrogen labeling.
• She wants the local androgen effect (prasterone raises intravaginal testosterone, which may further support sexual response at the tissue level) [14].
• She has estrogen-receptor-positive breast cancer and her oncologist prefers a non-estrogen agent, though data in this population remain limited [17].

Vaginal estradiol may be preferred when:

• Cost is a concern (generic vaginal estradiol cream is substantially less expensive than Intrarosa).
• The woman already uses estrogen-containing systemic HRT and formulation consistency is desired.
• She needs flexible dosing (cream can be titrated; the Intrarosa insert is a fixed 10 mg dose) [11].

A 2022 randomized controlled trial (N=240) comparing intravaginal prasterone 6.5 mg (lower than the U.S.-approved 10 mg) to estradiol cream found no statistically significant difference in FSFI scores or vaginal maturation index at 12 weeks, with both groups showing similar tolerability [18].

Safety Considerations Across All Four Options

The FDA's label for Addyi carries a boxed warning, the agency's strongest safety warning, for severe hypotension and syncope with alcohol co-ingestion [6]. No boxed warning appears on Vyleesi's label, but its cardiovascular contraindications are clinically serious [8].

Local vaginal estrogen carries minimal systemic risk. The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin 141 states that low-dose vaginal estrogen is safe for most women, including many breast cancer survivors, when systemic HRT would otherwise be contraindicated [19]. Women with hormone-receptor-positive breast cancer using aromatase inhibitors should discuss vaginal estrogen use with their oncologist before initiating, given the theoretical concern about any systemic estrogen rise [19].

Prasterone's safety profile at 52 weeks shows no endometrial stimulation and no significant change in serum estradiol beyond normal postmenopausal variation [16]. Long-term data beyond 52 weeks are not yet available from randomized trials.

Women considering any of these treatments should also be evaluated for testosterone deficiency, thyroid dysfunction, mood disorders, and relationship factors, all of which can suppress sexual desire independently of the pathways these drugs target [3].

Practical Prescribing Notes

Addyi requires enrollment in the ADDYI REMS program before dispensing, which means both prescriber and pharmacy must be REMS-certified [6]. Vyleesi does not have a REMS requirement but does require training on autoinjector use [8]. Both drugs are Schedule-free (not controlled substances). Neither is covered consistently by commercial insurance; out-of-pocket costs are typically $400, $800 per month without manufacturer coupons.

Generic vaginal estradiol cream costs as little as $30, $60 per month at most retail pharmacies. Intrarosa (prasterone) has no generic equivalent as of early 2025 and typically costs $300, $450 monthly without insurance, though manufacturer patient-assistance programs are available [15].

Telehealth platforms can prescribe all four treatments in states that allow synchronous or asynchronous visits for sexual medicine. Women pursuing Addyi through telehealth should confirm the prescribing platform is REMS-certified.

Across all four options, the highest-yield clinical step before prescribing is a validated screening instrument. The Female Sexual Function Index (FSFI) and the Female Sexual Distress Scale-Revised (FSDS-R) together take under five minutes to complete and confirm that desire symptoms cause meaningful distress, a requirement for both the diagnosis of HSDD and insurance prior authorization for Addyi or Vyleesi [2].

When None of These Drugs Is the Right Answer

Female sexual dysfunction does not always have a pharmacological solution. Relationship conflict, prior sexual trauma, body-image concerns, and partner sexual dysfunction are among the factors that psychotherapy and couples counseling address more directly than any of the four drugs discussed here [3]. The ISSWSH recommends sex therapy or cognitive behavioral therapy as first-line treatment for HSDD when a psychosocial contribution is identified [2].

SSRIs and SNRIs reduce sexual desire and delay orgasm in a substantial proportion of women; switching antidepressants or adding bupropion 150 to 300 mg daily may restore desire without requiring an HSDD-specific agent [20]. Bupropion is not FDA-approved for HSDD but has been studied in small randomized trials showing significant FSFI desire-domain improvements at 8 weeks compared with placebo [20].

Hormonal contraceptives, particularly combined oral contraceptives containing levonorgestrel or other androgenic progestins, may suppress desire via sex-hormone-binding globulin elevation and free-testosterone reduction; switching to a non-hormonal method or a progestin with lower SHBG effect may resolve symptoms without any additional pharmacotherapy [3].

The FSFI cutoff score for female sexual dysfunction is <26.55 across all six domains, and the desire subdomain score of <3.3 (out of 6) identifies low desire specifically [2]. A clinician who confirms a desire-domain score below this threshold, rules out reversible causes, and confirms personal distress has met the diagnostic standard for HSDD and can proceed to a pharmacological conversation with confidence.